The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Acquired | Acquired

About Sirion Biotech

SIRION Biotech is a viral vector technology company for gene and cell therapy, including vaccine development. The company offers comprehensive viral vector technology platforms based on lentiviruses, adenoviruses, and adeno-associated viruses (AAV) custom engineering, and manufacturing to expedites gene therapy research, cell therapy research, and advance drug development. It is based in Martinsried, Germany.On June 22, 2021, Sirion Biotech was acquired by PerkinElmer. The terms of the transaction were not disclosed.

Sirion Biotech Headquarter Location

Am Klopferspitz 19

Martinsried, 82152,


+49 89 700 961 99 9

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Sirion Biotech

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Sirion Biotech is included in 1 Expert Collection, including Regenerative Medicine.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Sirion Biotech Patents

Sirion Biotech has filed 9 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Biotechnology
  • Transcription factors
patents chart

Application Date

Grant Date


Related Topics




Molecular biology, Transcription factors, Biotechnology, Genetics, Virology


Application Date


Grant Date



Related Topics

Molecular biology, Transcription factors, Biotechnology, Genetics, Virology



Latest Sirion Biotech News

SIRION Biotech Achieves ISO-9001:2015 Certification

Mar 1, 2022

SIRION Biotech GmbH is proud to announce our achievement of ISO 9001:2015 certification by DEKRA. ISO 9001 is the worlds most widely recognized standard for a quality management system (QMS). It enables companies to operate more effectively on several different levels, including the ability to focus on customer requirements and constantly finding ways in which to improve and become resilient and sustainable. This ISO 9001:2015 certification reinforces SIRION's ability to exceed the quality expectations and requirements of our customers. "We are proud of our commitment to serving the scientific community, in particular cell and gene therapy developers, with the highest quality viral vectors" said Dieter Lingelbach, Chief Operations Officer at SIRION Biotech. "Customer satisfaction is at the center of everything we do and this ISO certification assures our customers that we continue to prioritize quality, reliability, and consistency in our manufacturing and management system processes today and in the future." In addition to ensuring that SIRION Biotech customers receive consistent, high-quality products and services, ISO 9001:2015 brings many business benefits. Our goals when embarking on certification were simple: • Homogenous, repeatable, and secure internal process execution • Creation of a platform for consistency during expansion • Improved client delivery services and customer satisfaction “We created a Quality Management Manual that recognizes the significant role our employees play in the quality of all SIRION Biotech services. This QMM, along with an existing quality assurance structure, provided the foundation for our ISO 9001:2015 Certification, and includes all aspects of Service Delivery, Business Enablement, Infrastructure, Human Resources and Training, Finance and Accounting, and Business Growth. It gives us a clear, actionable, and thorough approach to the vital components of our business and is positions us well for ongoing growth” said Katrin Becker, Head of Quality Assurance. Anlagen

  • When was Sirion Biotech founded?

    Sirion Biotech was founded in 2005.

  • Where is Sirion Biotech's headquarters?

    Sirion Biotech's headquarters is located at Am Klopferspitz 19, Martinsried.

  • What is Sirion Biotech's latest funding round?

    Sirion Biotech's latest funding round is Acquired.

  • Who are the investors of Sirion Biotech?

    Investors of Sirion Biotech include PerkinElmer, KfW, Creathor Ventures, Bayern Kapital, High-Tech Grunderfonds and 3 more.

  • Who are Sirion Biotech's competitors?

    Competitors of Sirion Biotech include HTG Molecular Diagnostics, MetaBiologics, Amnis Corporation, WaferGen Bio-systems, Life Technologies Corporation and 12 more.

You May Also Like

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.

Occam Research

The RDSP was created to help investigators identify funding opportunities and provide assistance to applicants. The RDSP staff work to stimulate research in cancer CAM and design activities that will develop the foundation of the science in cancer CAM research. RDSP programs include a series of Expert Panels on Research Methodologies in Cancer, an Invited Speakers Series, and technical assistance to help investigators prepare grant applications in cancer CAM.


Proteoplex is a spinout of Incyte Genomics and aims to provide the scientific community with key functional genomic and proteomic tools and services in the areas of Gene Expression, Protein Expression and Cell-Based Assays. The proteomics product addresses a major barrier in defining the function of proteins in cells; how to quickly and cheaply test thousands of samples for the presence of a particular set of proteins. This protein product will be closely followed by the launch of gene expression products to solve a similar barrier in the genomics market; how to quickly and cheaply interrogate thousands of samples against a defined set of important genes.

Flamma Logo

Flamma specializes in the manufacture of active ingredients and intermediates for the pharmaceutical, nutraceutical and cosmetic industries.

Bio::Neos Logo

Bio::Neos aims to provide bioinformatics software tools to aid commercial and academic research groups in efficiently and effectively performing genomics-enabled research. The company specialize in mutation identification research and custom software solutions specifically developed to meet the needs of research groups of any size.

Novacta Biosystems

Aiming to leverage the knowledge of GSK's Biotransformation and Natural Products scientific team, Novacta Biosystems Ltd was founded in 2003. In the following 5 years, Novacta successfully adopted a dual business model, whereby it developed a biocatalysis and microbial pathway engineering service business, that supported its efforts to build an infectious disease therapeutic pipeline.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.